Drug Profile
INGN 234
Alternative Names: p53 gene therapy - Introgen/Colgate-Palmolive; p53 topical - Introgen/Colgate-PalmoliveLatest Information Update: 18 Feb 2010
Price :
$50
*
At a glance
- Originator Introgen Therapeutics
- Class
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leucoplakia; Orofacial cancer
Most Recent Events
- 18 Feb 2010 Discontinued - Phase-II for Leucoplakia in USA (Buccal)
- 18 Feb 2010 Discontinued - Phase-II for Orofacial cancer in USA (Buccal)
- 26 Aug 2008 Phase-II clinical trials in Leucoplakia in USA (Buccal)